BioNTech SE Change in Accounts Receivable 2019-2025 | BNTX

BioNTech SE change in accounts receivable for the twelve months ending June 30, 2025 was $2.499B, a 84.23% decline year-over-year.

  • BioNTech SE annual change in accounts receivable for 2024 was $0.42B, a 92.79% decline from 2023.
  • BioNTech SE annual change in accounts receivable for 2023 was $5.816B, a 26.33% increase from 2022.
  • BioNTech SE annual change in accounts receivable for 2022 was $4.604B, a 132.96% decline from 2021.

BioNTech SE Change in Accounts Receivable 2019-2025 | BNTX

  • BioNTech SE annual change in accounts receivable for 2024 was $0.42B, a 92.79% decline from 2023.
  • BioNTech SE annual change in accounts receivable for 2023 was $5.816B, a 26.33% increase from 2022.
  • BioNTech SE annual change in accounts receivable for 2022 was $4.604B, a 132.96% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$251.1B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$101.3B
Bristol Myers Squibb (BMY)$97.5B
GSK (GSK)$81.9B
CSL (CSLLY)$68.2B
Regeneron Pharmaceuticals (REGN)$62.5B
Alnylam Pharmaceuticals (ALNY)$59.6B
Argenex SE (ARGX)$40.4B
Insmed (INSM)$27.9B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.1B
Genmab (GMAB)$15.8B
Illumina (ILMN)$15.6B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Moderna (MRNA)$10.6B
Exelixis (EXEL)$10.4B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.9B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Guardant Health (GH)$7.7B